LIMITATIONS
Our study was a single-center, cross-sectional study, and we did not
follow patients to document their various cardiac endpoints. The sample
size was relatively low and further large scale studies may illuminate
the use of copeptin levels in UA patients as a prognostic marker. Even
though we tried to include only UA cases in the study, based on
available clinical and laboratory data (the hsTn values at hour 0 and at
hour 6), it should be noted that some of the participants may also be
NSTEMI patients and despite every diagnostic attempt we could be unable
to detect these patients. Another limitation is that there is currently
no consensus regarding the correct sampling time for copeptin levels.